HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report

Abstract

The global prevalence of hepatitis C virus (HCV) infection is approximately 3%, with a post-infection chronicity rate of up to 50%–85%. HCV reactivation can occur when anti-HCV positive individuals receive antineoplastic therapy. In this study, we report a case of an anti-HCV positive patient with negative HCV RNA after 12 weeks of direct antiviral therapy. Two months later, sorafenib was used to treat hepatocellular carcinoma, and HCV reactivation occurred after 8 months of the treatment. HCV RNA was negative after 12 weeks of antiviral treatment with Sofosbuvir-velpatasvir. We also discussed the mechanism of HCV reactivation caused by sorafenib and the antiviral treatment regimen after HCV reactivation with the relevant literature.

Keywords:

• hepatocellular carcinoma
• sorafenib
• HCV-RNA
• anti-HCV therapy
• reactivation

Ethics and Consent Statements

The patient provided informed consent to publish their case details and any accompanying images. The institutional approval was not required to publish the case details.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This work was supported by Natural Science Research Project of Higher Education Institutions in Anhui Province (KJ2021A0285).